MGMT and medulloblastoma: The synergistic effect was based on the reduction of β-catenin by CK2-inhibition, which in turn reduced O-6-methylguanine-DNA methyltransferase (MGMT), thereby increasing the sensitivity of medulloblastoma cells to TMZ treatment [539].